PerkinElmer to Focus on Applications, Small Acquisitions as Friel Prepares to Take Helm | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
As Rob Friel prepares to take over as CEO of PerkinElmer early next year, he told investors this week that he will continue to focus the company on specific applications rather than on specific technologies and that the firm is likely to proceed with its strategy of making smaller acquisitions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.